Skip to main content

Table 2 Treatment and outcome of the 37 patients with nongestational choriocarcinoma

From: Clinical features of a Chinese female nongestational choriocarcinoma cohort: a retrospective study of 37 patients

Surgical operations

 

 Laparotomy

31 (83.8%)

 Laparoscopic surgery

4 (10.8%)

 Craniotomy

2 (5.4%)

Chemotherapy

 

Total number of courses, median (range)

7.5 (1–43)

 Number of courses before CR, median (range)

4.0 (1–27)

 Regimen

 

  EMACO

20 (54.1%)

  FAEV

17 (45.9%)

  BEP

7 (18.9%)

  PVB

4 (10.8%)

  ICE

2 (5.4%)

Outcome

 

 CR

30 (81.1%)

  Relapse

5 (16.7%)

 PR

4 (10.8%)

 PD

3 (8.1%)

  1. CR complete response, PR partial response, PD progressive disease, EMACO Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide, and Vincristine, FAEV Floxuridine, Actinomycin-D, Etoposide, and Vincristine, BEP Bleomycin, Etoposide, and Cisplatin, PVB Bleomycin, Vincristine, and Cisplatin, ICE Ifosfamide, Carboplatin, and Etoposide